Invivyd Aligns with FDA for Rapid Approval Pathway

Invivyd ( (IVVD) ) just unveiled an update.

On August 14, 2025, Invivyd announced its alignment with the U.S. FDA on a rapid pathway to full approval for its monoclonal antibody candidate VYD2311, aimed at protecting against COVID-19. The company reported significant financial growth in the second quarter of 2025, with a 413% year-over-year increase in PEMGARDA® revenue, despite not achieving near-term profitability. Invivyd is also advancing its clinical trials and expanding its pipeline, with plans for a Phase 2/3 trial for VYD2311 and potential RSV and measles candidates. These developments indicate a strategic push to solidify its position as a leader in monoclonal antibody technology for COVID-19 protection.

The most recent analyst rating on (IVVD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.

To see Spark’s full report on IVVD stock, click here.

More about Invivyd

Invivyd, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibodies as alternatives to vaccines for infectious diseases, including COVID-19. The company is known for its products like PEMGARDA® (pemivibart) and is actively expanding its pipeline to include treatments for other viruses such as RSV and measles.

Average Trading Volume: 1,284,003

Technical Sentiment Signal: Sell

Current Market Cap: $93.61M

Find detailed analytics on IVVD stock on TipRanks’ Stock Analysis page.